Supplementary Figure from Plasma Protein Biomarkers in Advanced or Metastatic Colorectal Cancer Patients Receiving Chemotherapy With Bevacizumab or Cetuximab: Results from CALGB 80405 (Alliance)
Publication
, Other
Nixon, AB; Sibley, AB; Liu, Y; Hatch, AJ; Jiang, C; Mulkey, F; Starr, MD; Brady, JC; Niedzwiecki, D; Venook, AP; Baez-Diaz, L; Lenz, H-J ...
March 31, 2023
Duke Scholars
Citation
APA
Chicago
ICMJE
MLA
NLM
Nixon, A. B., Sibley, A. B., Liu, Y., Hatch, A. J., Jiang, C., Mulkey, F., … Hurwitz, H. I. (2023). Supplementary Figure from Plasma Protein Biomarkers in Advanced or Metastatic Colorectal Cancer Patients Receiving Chemotherapy With Bevacizumab or Cetuximab: Results from CALGB 80405 (Alliance). https://doi.org/10.1158/1078-0432.22483458.v1
Nixon, Andrew B., Alexander B. Sibley, Yingmiao Liu, Ace J. Hatch, Chen Jiang, Flora Mulkey, Mark D. Starr, et al. “Supplementary Figure from Plasma Protein Biomarkers in Advanced or Metastatic Colorectal Cancer Patients Receiving Chemotherapy With Bevacizumab or Cetuximab: Results from CALGB 80405 (Alliance),” March 31, 2023. https://doi.org/10.1158/1078-0432.22483458.v1.
Nixon AB, Sibley AB, Liu Y, Hatch AJ, Jiang C, Mulkey F, et al. Supplementary Figure from Plasma Protein Biomarkers in Advanced or Metastatic Colorectal Cancer Patients Receiving Chemotherapy With Bevacizumab or Cetuximab: Results from CALGB 80405 (Alliance). 2023.
Nixon, Andrew B., et al. Supplementary Figure from Plasma Protein Biomarkers in Advanced or Metastatic Colorectal Cancer Patients Receiving Chemotherapy With Bevacizumab or Cetuximab: Results from CALGB 80405 (Alliance). 31 Mar. 2023. Crossref, doi:10.1158/1078-0432.22483458.v1.
Nixon AB, Sibley AB, Liu Y, Hatch AJ, Jiang C, Mulkey F, Starr MD, Brady JC, Niedzwiecki D, Venook AP, Baez-Diaz L, Lenz H-J, O’Neil BH, Innocenti F, Meyerhardt JA, O’Reilly EM, Owzar K, Hurwitz HI. Supplementary Figure from Plasma Protein Biomarkers in Advanced or Metastatic Colorectal Cancer Patients Receiving Chemotherapy With Bevacizumab or Cetuximab: Results from CALGB 80405 (Alliance). 2023.